A comprehensive review of the therapeutic potential of curcumin nanoformulations.
Khadijeh KhezriMajid SaeediHassan MohammadaminiAbbas Seyed ZakaryaeiPublished in: Phytotherapy research : PTR (2021)
Today, due to the prevalence of various diseases such as the novel coronavirus (SARS-CoV-2), diabetes, central nervous system diseases, cancer, cardiovascular disorders, and so on, extensive studies have been conducted on therapeutic properties of natural and synthetic agents. A literature review on herbal medicine and commercial products in the global market showed that curcumin (Cur) has many therapeutic benefits compared to other natural ingredients. Despite the unique properties of Cur, its use in clinical trials is very limited. The poor biopharmaceutical properties of Cur such as short half-life in plasma, low bioavailability, poor absorption, rapid metabolism, very low solubility (at acidic and physiological pH), and the chemical instability in body fluids are major concerns associated with the clinical applications of Cur. Recently, nanoformulations are emerging as approaches to develop and improve the therapeutic efficacy of various drugs. Many studies have shown that Cur nanoformulations have tremendous therapeutic potential against various diseases such as SARS-CoV-2, cancer, inflammatory, osteoporosis, and so on. These nanoformulations can inhibit many diseases through several cellular and molecular mechanisms. However, successful long-term clinical results are required to confirm their safety and clinical efficacy. The present review aims to update and explain the therapeutic potential of Cur nanoformulations.
Keyphrases
- sars cov
- papillary thyroid
- clinical trial
- type diabetes
- respiratory syndrome coronavirus
- squamous cell
- cardiovascular disease
- risk factors
- squamous cell carcinoma
- health insurance
- bone mineral density
- postmenopausal women
- randomized controlled trial
- case report
- body composition
- young adults
- adipose tissue
- ionic liquid
- childhood cancer
- glycemic control
- phase ii
- metabolic syndrome
- double blind
- study protocol
- quantum dots